Advanced renal cell carcinoma: current and emerging management strategies.

abstract：:Aflibercept (Eylea(®)) is an anti-vascular endothelial growth factor agent indicated for intravitreal use in the treatment of diabetic macular oedema. In patients with diabetic macular oedema, significantly greater improvements from baseline to week 52 in visual acuity were seen with intravitreal aflibercept versus ma...

journal_title：Drugs

authors： Keating GM

更新日期：2015-07-01 00:00:00

abstract：:Preclinical studies indicate that angiogenic growth factors can stimulate the development of collateral arteries in animal models of peripheral or myocardial ischaemia, a concept termed 'therapeutic angiogenesis'. The goal of this review is to provide a brief overview of the advantages and disadvantages of gene versus...

journal_title：Drugs

authors： Amant C,Berthou L,Walsh K

更新日期：1999-01-01 00:00:00

abstract：:The corticosteroid mometasone and the long-acting β(2)-selective adrenoreceptor agonist formoterol have been combined in a single pressurized metered-dose inhaler for use in patients aged ≥12 years with asthma. In a 26-week well designed trial in patients with persistent asthma uncontrolled on medium-dose inhaled cort...

journal_title：Drugs

authors： Frampton JE

更新日期：2012-06-18 00:00:00

abstract：:Nausea and vomiting is a common and distressing symptom complex in patients with far-advanced cancer, affecting up to 60% of individuals at some stage of their illness. The current approach to the palliative care of patients with nausea and vomiting is based on identifying the cause, understanding its pathophysiology ...

journal_title：Drugs

authors： Glare PA,Dunwoodie D,Clark K,Ward A,Yates P,Ryan S,Hardy JR

更新日期：2008-01-01 00:00:00

abstract：:Flecainide is a Class I antiarrhythmic drug of the local anaesthetic type. It can be given either intravenously or orally and its pharmacokinetic properties allow relatively long (12 hours) dosing intervals with oral administration. In several open and a few controlled therapeutic trials, orally administered flecainid...

journal_title：Drugs

authors： Holmes B,Heel RC

更新日期：1985-01-01 00:00:00

abstract：:Lefamulin is a novel oral and intravenous (IV) pleuromutilin developed as a twice-daily treatment for community-acquired bacterial pneumonia (CABP). It is a semi-synthetic pleuromutilin with a chemical structure that contains a tricyclic core of five-, six-, and eight-membered rings and a 2-(4-amino-2-hydroxycyclohexy...

journal_title：Drugs

authors： Zhanel GG,Deng C,Zelenitsky S,Lawrence CK,Adam HJ,Golden A,Berry L,Schweizer F,Zhanel MA,Irfan N,Bay D,Lagacé-Wiens P,Walkty A,Mandell L,Lynch JP 3rd,Karlowsky JA

更新日期：2020-11-28 00:00:00

abstract：:Despite well known complications, oral nonsteroidal anti-inflammatory drugs (NSAIDs) remain the most commonly prescribed medications in the US for musculoskeletal disorders such as osteoarthritis. Although there has been a recent focus on the cardiovascular and renal complications associated with these agents, NSAID g...

journal_title：Drugs

authors： Roth SH

更新日期：2012-05-07 00:00:00

abstract：:The article Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer, written by Connie Kang, Sohita Dhillon and Emma D. Deeks, was originally published Online First without open access. ...

journal_title：Drugs

authors： Kang C,Dhillon S,Deeks ED

更新日期：2019-10-01 00:00:00

abstract：:Nizatidine is an H2-receptor antagonist which in animal studies was more active on a weight-for-weight basis than cimetidine in inhibiting basal and stimulated gastric acid secretion. Similarly, studies in humans have confirmed that nizatidine is a potent inhibitor of basal, nocturnal and stimulated gastric acid secre...

journal_title：Drugs

authors： Price AH,Brogden RN

更新日期：1988-11-01 00:00:00

abstract：:Tipranavir (Aptivus) is a selective nonpeptidic HIV-1 protease inhibitor (PI) that is used in the treatment of treatment-experienced adults with HIV-1 infection. Tipranavir is administered orally twice daily and must be given in combination with low-dose ritonavir, which is used to boost its bioavailability. The durab...

journal_title：Drugs

authors： Orman JS,Perry CM

更新日期：2008-01-01 00:00:00

abstract：:In the 30 years since the rabbit antithymocyte globulin (rATG) Thymoglobulin(®) was first licensed, its use in solid organ transplantation and hematology has expanded progressively. Although the evidence base is incomplete, specific roles for rATG in organ transplant recipients using contemporary dosing strategies are...

journal_title：Drugs

authors： Mohty M,Bacigalupo A,Saliba F,Zuckermann A,Morelon E,Lebranchu Y

更新日期：2014-09-01 00:00:00

abstract：:The rapid spread of human immunodeficiency virus (HIV) infections and the grim outcome of these infections have focused interest on the possibilities for medical intervention. The end-stage of these infections, acquired immune deficiency syndrome (AIDS), was first recognised in 1981, and the causative agent isolated i...

journal_title：Drugs

authors： Sandström EG,Kaplan JC

更新日期：1987-09-01 00:00:00

abstract：:Page 9, Fig. 2, which originally appeared as. ...

journal_title：Drugs

authors： Mathieson S,Maher CG,Ferreira GE,Hamilton M,Jansen J,McLachlan AJ,Underwood M,Lin CC

更新日期：2020-10-01 00:00:00

abstract：:Diabetic gastroparesis is a common and debilitating condition affecting millions of patients with diabetes mellitus worldwide. Although gastroparesis in diabetes has been known clinically for more than 50 years, treatment options remain very limited. Until recently, the scientific literature has offered few clues rega...

journal_title：Drugs

authors： Smith DS,Ferris CD

更新日期：2003-01-01 00:00:00

abstract：:The newest (third generation) fluoroquinolones are potentially useful agents in the management of community-acquired respiratory tract infections. This is mainly due to their increased activity against Streptococcuspneumoniae, a pathogen poorly susceptible to the second-generation compounds, and playing a major role i...

journal_title：Drugs

authors： Momméja-Marin H,Carbon C

更新日期：1999-06-01 00:00:00

abstract：:The oral deoxyguanosine nucleoside analogue entecavir (Baraclude®) has potent activity against hepatitis B virus (HBV) and a high genetic barrier to resistance. This article reviews the clinical efficacy and tolerability of entecavir in the treatment of chronic hepatitis B in patients with decompensated liver disease,...

journal_title：Drugs

authors： Keating GM

更新日期：2011-12-24 00:00:00

abstract：:The current challenge facing clinicians is to develop pharmacotherapies that move beyond the treatment of symptoms towards a new agenda in cardiovascular therapeutics that includes interventions to actually prevent the development of end-stage coronary heart disease. The development of new strategies to alter the natu...

journal_title：Drugs

authors： Gibbons GH

更新日期：1997-01-01 00:00:00

abstract：:Ascletis has developed danoprevir (Ganovo®), an orally-administered hepatitis C virus NS3 protease inhibitor, as a treatment for hepatitis C. Based on positive results in phase II and phase III trials in patients with hepatitis C, danoprevir, in combination with ritonavir, peginterferon alfa and ribavirin was recently...

journal_title：Drugs

authors： Markham A,Keam SJ

更新日期：2018-08-01 00:00:00

abstract：:The incidence of adenocarcinoma of the pancreas has risen steadily over the past 4 decades. Since pancreatic cancer is diagnosed at an advanced stage, and because of the lack of effective therapies, the prognosis of such patients is extremely poor. Despite advances in our understanding of the molecular biology of panc...

journal_title：Drugs

authors： Rosenberg L

更新日期：2000-05-01 00:00:00

abstract：UNLABELLED:5-Methoxypsoralen, a naturally occurring linear furocoumarin, has been successfully used in combination with ultraviolet (UV) A irradiation [psoralen plus UV (PUVA)] to manage psoriasis and vitiligo. In patients and volunteers, PUVA 5-methoxypsoralen causes a dose-related increase in cutaneous photosensitivi...

journal_title：Drugs

authors： McNeely W,Goa KL

更新日期：1998-10-01 00:00:00

abstract：:This article is intended to stimulate thought and focus on those areas where we feel advances in drug therapy for inflammatory bowel disease may occur. It is not an extensive review of current practice, although this is considered where it is thought to be pertinent to future developments. There are several excellent ...

journal_title：Drugs

authors： Rhodes J,Thomas G,Evans BK

更新日期：1997-02-01 00:00:00

abstract：:Several large-scale clinical trials have assessed the efficacy of atorvastatin in the primary and secondary prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. In primary prevention, CARDS (Collaborative Atorvastatin Diabetes Study) showed that atorvastatin 10 mg/day (vs p...

journal_title：Drugs

authors： Arca M

更新日期：2007-01-01 00:00:00

abstract：:Numerous studies report the relationship between aspirin and other nonsteroidal anti-inflammatories (NSAIDs) and cancer incidence, in particular for colorectal cancer. This paper systematically reviews the evidence of the effect of aspirin and other NSAIDs on the primary prevention of colorectal and other gastrointest...

journal_title：Drugs

authors： Jolly K,Cheng KK,Langman MJ

更新日期：2002-01-01 00:00:00

abstract：:Tuberculosis continues to be a major cause of disease and death throughout the developing world. Chemotherapy is the current method of control but with the continuing emergence of drug resistance, coupled with the reticence of major drug companies to invest in drug discovery, the identification of new vaccines to comb...

journal_title：Drugs

authors： Orme IM

更新日期：2005-01-01 00:00:00

abstract：:Canagliflozin (Invokana™), an oral selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, is under global development with Mitsubishi Tanabe Pharma and Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson, for the treatment of type 2 diabetes mellitus. SGLT2 are mainly located in the proximal tubule of t...

journal_title：Drugs

authors： Elkinson S,Scott LJ

更新日期：2013-06-01 00:00:00

abstract：:Brodalumab (Lumicef(®)) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Brodalumab binds with high affinity to interleukin (IL)-...

journal_title：Drugs

authors： Greig SL

更新日期：2016-09-01 00:00:00

abstract：:Health behaviors such as retention in HIV medical care and adherence to antiretroviral therapy (ART) pose major challenges to reducing new HIV infections, addressing health disparities, and improving health outcomes. Andersen's Behavioral Model of Health Service Use provides a conceptual framework for understanding ho...

journal_title：Drugs

authors： Holtzman CW,Brady KA,Yehia BR

更新日期：2015-04-01 00:00:00

abstract：:Vivus' proprietary oral capsule containing phentermine and extended-release (ER) topiramate has been approved in the US for the treatment of obesity. Phentermine is an appetite suppressant, while topiramate is an anti-epileptic medication. The once-daily formulation, known as Qsymia™, is designed to produce weight los...

journal_title：Drugs

authors： Cameron F,Whiteside G,McKeage K

更新日期：2012-10-22 00:00:00

abstract：:Coronary arterial thrombolysis is becoming an established treatment of acute myocardial infarction. If given early enough, it recanalises occluded coronary arteries, salvages myocardial function and reduces mortality. A reduction of mortality in patients with acute myocardial infarction has now been demonstrated for s...

journal_title：Drugs

authors： Collen D,Lijnen HR,Todd PA,Goa KL

更新日期：1989-09-01 00:00:00

abstract：:Lung function can be reduced not only by a non-selective beta-blocker but also by a selective beta1-receptor blocker. If both types of drug are without intrinsic sympathomimetic activity, the effect of the non-selective drug is more pronounced than that of a beta1-receptor selective drug under basal conditions. The ef...

journal_title：Drugs

authors： Johnsson G

更新日期：1976-01-01 00:00:00